Head-to-head evidence
dasiglucagon vs Nasal Glucagon
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Glucagon receptor (agonist) · full Type 2 Diabetes pipeline
dasiglucagon · Zegalogue
Marketed by Zealand Pharma
NCT03378635 · Phase 3 · completed
Adults with type 1 diabetes were randomly assigned in a quadruple-blind trial to dasiglucagon, placebo, or GlucaGen, with 170 participants randomized and 168 receiving treatment. The primary clinical endpoint was met: median time to plasma glucose recovery was 10 minutes with dasiglucagon versus 40 minutes with placebo (p<0.001).
Nasal Glucagon · Baqsimi
Marketed by Amphastar Pharmaceuticals, Inc. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dasiglucagon's landscape · Nasal Glucagon's landscape